Business

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology

Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving response rates and enhancing patient outcomes across multiple indications THE WOODLANDS, TX, March 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing

articleAutonomix Medical, Inc.March 20, 20254/company/autonomix-medical-inc-common-stock/news/autonomix-medical-inc-granted-u-123000546
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology

About this update from Autonomix Medical, Inc.

[{"type":"image","alt":"Autonomix Medical, Inc.","displaySize":"","headline":null,"caption":"Autonomix Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":174,"url":"https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yXZC_k658ygjAcliUe7Yow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5cca67be9740fed2b1f7fe47e0e265b6","width":300,"height":174}},"lazy":false},{"type":"text","content":"Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications ","length":116,"tagName":"p"},{"type":"text","content":"Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving response rates and enhancing patient outcomes across multiple indications","length":212,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, TX, March 20, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. patent 12,217,863 (‘863 patent) titled, Medical Devices with Circuitry for Capturing and Processing Physiological Signals. The issued ‘863 patent gives Autonomix protection of proprietary technology used to collect and process sensing data for real-time physiological monitoring with broad application use that includes, e.g., heart mapping, arterial mapping, parenchymal monitoring, central nervous system monitoring and implant, robotic and wearable precision applications.","length":847,"tagName":"p"},{"type":"text","content":"“We are pleased to strengthen our patent protection for this potential groundbreaking technology. The continued positive data on its application, efficacy, and safety reinforce our confidence in its potential. We remain committed to advancing this innovation to address critical areas of unmet medical need. To date, our early clinical results have been highly encouraging for reducing pancreatic cancer pain. Beyond cancer pain, our technology holds promise for a broad range o...

More updates from Autonomix Medical, Inc.

Autonomix Medical, Inc.proprietary technologyUnited States Patent and Trademark Officechronic pain managementmedical device companyCompanyThe Companyinnovative technologiestreatment for pancreatic cancertechnologyperipheral nervous systempancreatic cancer